Biocon, Celgene settle patent litigation over cancer drug Revlimid
New Delhi: Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a medication used to treat bone marrow cancer.
The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.
It did not share details of the agreement.
Read also: Biocon Biologics, Adagio Therapeutics join hands to advance antibody for COVID treatment
Celgene had filed a complaint in the US, against Biocon for potential patent infringement.
Read also: Biocon Biologics, Viatris get USFDA nod for first interchangeable biosimilar Semglee for diabetes
